🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Valiant Laboratories Limited VALIANTLAB NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://valiantlabs.in
Company Profile ↓
₹61.23
-34.61% 1Y
Mkt Cap₹332.56 Cr
P/E-120.06
P/B1.09
52W High₹93.64
52W Low₹50.93
Book Value₹56.57
EPS (TTM)₹-0.51

Company Overview

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Recent Developments

  • Mar 2026 Revenue of ₹237.47 Cr (+78.0% YoY); net profit ₹-3.27 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +59.2%, earnings +104.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR -10.7%, profit CAGR -37.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-10.74%
1 Year:59.20%

Compounded Profit Growth

5 Years:-37.09%
1 Year:104.20%

Stock Price Performance

1 Year:-34.61%
6 Months:+4.22%
3 Months:-23.41%
1 Month:-6.53%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 24% of range
₹50.93 ₹93.64
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • Death Cross5d ago
  • RSI (14)39.26 · Neutral
Price Performance
1M-6.53%
3M-23.41%
6M+4.22%
1Y-34.61%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -10.7% CAGR over 5 years.
  • Earnings shrank at -37.1% CAGR over 5 years.
  • Trading 34.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-120.06
Industry PE
35.94
Forward P/E
-
PEG Ratio
-
Book Value
₹56.57
Price to Book
1.09
P/S
1.41
EV/EBITDA
54.96
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-10.74%
Profit 5Y
-37.09%
Revenue (YoY)
59.20%
Earnings (YoY)
104.20%

Profitability & Returns

ROCE
0.78%
ROE
-1.20%
ROA
0.05%
Profit Margin
-1.38%
Op Margin
2.05%
Gross Margin
16.97%
EPS (Latest Qtr)
₹0.32
EPS (TTM)
₹-0.51

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
1.06
Current Ratio
1.91
Debt
₹46.21 Cr
Total Assets
₹463.98 Cr
Current Assets
₹228.32 Cr
Working Capital
₹108.88 Cr

Ownership

Promoter Holding
76.78%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹332.56 Cr
Total Revenue (TTM)
₹237.47 Cr
EBITDA
₹6.39 Cr
Free Cash Flow
₹-48.49 Cr
Operating Cash Flow
₹-10.43 Cr
Shares Outstanding
₹5.43 Cr
Gross Margin
16.97%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VALIANTLAB Valiant Laboratories Limited NSEPHARMA 61.23 -120.06 ₹332.56 Cr 0.00% 0.78% -1.20% -10.74% -37.09%
2 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,974.50 66.71 ₹1.29 L Cr 0.22% 19.79% 21.50% 15.33% 33.34%
3 ALKEM Alkem Laboratories Limited NIFTY_MIDNSEPHARMA 5,597.50 29.07 ₹66,926.51 Cr 0.35% 18.56% 17.56% 8.30% 32.74%
4 ABBOTINDIA Abbott India Limited NIFTY_MIDNSEPHARMA 27,855.00 38.12 ₹59,189.93 Cr 1.89% 41.87% 34.46% 9.01% 17.80%
5 ANTHEM ANTHEM BIOSCIENCES LTD NIFTY_MIDNSEPHARMA 825.65 81.26 ₹46,377.90 Cr 0.24% 26.77% 19.45% 26.20% 15.39%
6 AJANTPHARM Ajanta Pharma Limited NIFTY_MIDNSEPHARMA 3,470.40 38.28 ₹43,357.66 Cr 1.86% 29.41% 23.33% 13.40% 21.55%
7 AGARWALEYE DR AGARWALS HEALTH CARE L NSEPHARMA 532.30 127.96 ₹16,875.30 Cr 0.00% 9.74% 6.58% 26.96% 12.28%
8 APLLTD Alembic Pharmaceuticals Limited NSEPHARMA 834.45 23.67 ₹16,402.21 Cr 1.49% 12.77% 12.36% 9.46% 25.42%
9 ALIVUS Alivus Life Sciences Limited NSEPHARMA 1,325.20 27.06 ₹16,265.43 Cr 0.38% 21.78% 16.94% 7.61% 6.53%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -57.79 Cr46.82 Cr46.20 Cr52.46 Cr91.98 Cr
Cost of Revenue -48.23 Cr39.72 Cr40.33 Cr44.97 Cr72.13 Cr
Gross Profit -9.56 Cr7.10 Cr5.87 Cr7.49 Cr19.85 Cr
Operating Expenses -6.25 Cr5.23 Cr6.33 Cr10.43 Cr17.97 Cr
Operating Income -3.31 Cr1.87 Cr-45.37 L-2.94 Cr1.89 Cr
EBITDA -1.51 Cr3.05 Cr94.46 L-26.01 L4.98 Cr
Interest Expense -5.45 L7.33 L13.59 L68.21 L1.01 Cr
Pretax Income -93.91 L2.45 Cr27.65 L-2.99 Cr1.05 Cr
Tax Provision -23.53 L62.79 L7.64 L4.07 Cr-71.19 L
Net Income -70.36 L1.82 Cr20.01 L-7.06 Cr1.76 Cr
Diluted EPS -0.160.390.04-1.440.32

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -333.91 Cr182.06 Cr133.38 Cr237.47 Cr
Cost of Revenue -284.71 Cr176.52 Cr116.60 Cr197.16 Cr
Gross Profit -49.20 Cr5.54 Cr16.78 Cr40.30 Cr
Operating Expenses -15.62 Cr15.91 Cr23.55 Cr39.95 Cr
Operating Income -33.58 Cr-10.38 Cr-6.77 Cr35.02 L
EBITDA -39.95 Cr1.27 Cr75.53 L8.71 Cr
Interest Expense -25.37 L7.78 L17.53 L1.90 Cr
Pretax Income -38.14 Cr-76.95 L-1.51 Cr76.82 L
Tax Provision -9.14 Cr-1.09 Cr68.86 L4.04 Cr
Net Income -29.00 Cr31.96 L-2.20 Cr-3.27 Cr
Diluted EPS 5.876.190.12-0.51-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -212.97 Cr342.69 Cr400.86 Cr463.98 Cr
Current Assets -150.58 Cr225.54 Cr192.62 Cr228.32 Cr
Cash & Equivalents -1.26 Cr11.72 Cr4.92 Cr3.53 Cr
Inventory -13.04 Cr10.02 Cr3.99 Cr45.43 Cr
Receivables -88.57 Cr45.72 Cr72.12 Cr93.56 Cr
Total Liabilities -112.47 Cr105.83 Cr166.55 Cr153.09 Cr
Current Liabilities -50.73 Cr29.08 Cr59.62 Cr119.45 Cr
Long Term Debt -59.40 Cr74.66 Cr104.35 Cr28.09 Cr
Total Debt -60.22 Cr76.71 Cr121.69 Cr46.21 Cr
Total Equity -100.49 Cr236.86 Cr234.31 Cr310.89 Cr
Shares Outstanding -4.68 Cr4.68 Cr4.68 Cr5.43 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -56.05 Cr1.89 Cr1.31 Cr-10.43 Cr
Investing Cash Flow --55.17 Cr-143.88 Cr-52.77 Cr7.25 Cr
Financing Cash Flow --93.39 L152.45 Cr44.65 Cr1.79 Cr
Capital Expenditure --37.68 Cr-45.87 Cr-113.85 Cr-34.20 Cr
Free Cash Flow -18.37 Cr-43.98 Cr-112.54 Cr-44.63 Cr
Net Change in Cash --5.10 L10.46 Cr-6.80 Cr-1.39 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -14.7%3.0%12.6%17.0%
Operating Margin % -10.1%-5.7%-5.1%0.1%
Net Margin % -8.7%0.2%-1.7%-1.4%
ROE % -28.9%0.1%-0.9%-1.1%
ROCE % -20.7%-3.3%-2.0%0.1%

Shareholding Pattern

Insiders
76.78%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VALIANTLAB

Google News Wed, 28 May 2025

VALIANTLAB Stock Price and Chart — NSE:VALIANTLAB - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1WaVRBTVJrR3p2dGtDVHMxbllHd3V5MXlsVmVLZW1wQ2R4cXQwZHZOcU03eUR4Ul9VSWVOYnpZLXFCLUVFM1dhMExOME9hczNqNFJTUHc0NUR6SXJ2aHQ4eg?oc=5" target="_blank">VALIANTLAB Stock Price and Chart — NS…

Google News hu, 05 Oct 2023

Valiant Laboratories Ltd Share Price Today | Valiant Lab Live NSE/BSE - Value Research

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxQNU0ydnhjTnJ6bWZJX2V1LUtqS2dGNHBIT21YRjl6T2p4V3JCT3F1VDl5ekpIY3hLS0M2MDJrRm16aEo3U2w5WFRldy1xdGI1ekkyZ2l3a3RWV2wtZjNldkxaal8xZWZxUnV0Nm96MFZQdkFxQmFad3RVRHl3Nkh0Zw?oc=5" target="_…

Google News ue, 03 Oct 2023

Pharma firm Valiant Lab IPO subscribed 29.75 times on last day of offer - business-standard.com

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOcHc5WnUtSW8zR0VSVEJtNEhkWUZwTGlqX3JMaHYzTzlJUEZQTk9feW9peXE2VTdEWFY2RE1rSm0tQXRkLXN0UFJaY21BOU4ySmVGMkZHbFc2UElKUERvOUtnMkh6bE5Ob0huYXJrRW1uVG9Yb0NZZk8zaXBsMUwyS2dsSmk3WEI1dmJZdj…

VALIANTLAB — Frequently Asked Questions

What is the current share price of Valiant Laboratories Limited (VALIANTLAB)?

As of 2026-08-07 06:31 IST, Valiant Laboratories Limited (VALIANTLAB) trades at ₹61.23 on NSE. Its 52-week range is ₹50.93 to ₹93.64.

What is the market capitalisation of VALIANTLAB?

Valiant Laboratories Limited (VALIANTLAB) has a market capitalisation of ₹332.56 Cr on NSE.

What is the P/E ratio of VALIANTLAB?

VALIANTLAB trades at a trailing price-to-earnings (P/E) ratio of -120.06. The industry average P/E is 35.94. Its price-to-book (P/B) ratio is 1.09.

What is the return on equity (ROE) of VALIANTLAB?

VALIANTLAB has a return on equity (ROE) of -1.20%. Its return on capital employed (ROCE) is 0.78%.

Is VALIANTLAB a good stock to buy?

This page provides a data-driven analysis of Valiant Laboratories Limited (VALIANTLAB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space